Publications

Gollins et al. reported that within this cohort, the Psoriatic arthritis response criteria (PsARC) response to 4^th+ lines of b/tsDMARD was not significantly reduced compared with 2^nd/3^rd line in participants who had failed at least 3 b/tsDMARDs. Authors evaluated the primary clinical response to sequential lines of b/tsDMARD therapy in PsA, focusing on the effectiveness of later line treatments.

The SEQUENCE study provides the first evidence of PsARC response in a UK cohort in lines of b/tsDMARD beyond 3^rd line. These results indicates that patients in a UK cohort can continue to have a meaningful response to later lines of treatment. Further prospective representative studies are required to better understand the effectiveness response in this population of difficult-to-treat patient.